Sanofi (XSWX:SAN) Short-Term Debt: CHF6,470 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:SAN Sanofi SA XSWX:SAN
91 GF Score
Price CHF73.20
GF Value CHF103.32
! 2 Warning Signs
View Full Analysis

What is Sanofi Short-Term Debt?

Sanofi XSWX:SAN 91 Short-Term Debt is CHF6,470 Mil as of Jun. 2026. GuruFocus rates XSWX:SAN with a GF Score™ of 91/100 and a GF Value™ of CHF103.32. The stock has 2 warning signs investors should review.

Sanofi's Short-Term Debt for the quarter that ended in Jun. 2026 was CHF6,470 Mil.

Sanofi's quarterly Short-Term Debt declined from Jun. 2025 (CHF6,855 Mil) to Dec. 2025 (CHF4,052 Mil) but then increased from Dec. 2025 (CHF4,052 Mil) to Jun. 2026 (CHF6,470 Mil).

Sanofi's annual Short-Term Debt increased from Dec. 2023 (CHF1,929 Mil) to Dec. 2024 (CHF3,930 Mil) and increased from Dec. 2024 (CHF3,930 Mil) to Dec. 2025 (CHF4,052 Mil).

Sanofi Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Sanofi Short-Term Debt Related Terms

Sanofi Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Sanofi's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Short-Term Debt Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,312.48 4,119.17 1,928.59 3,929.58 4,051.69

Sanofi Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,886.05 3,929.58 6,855.45 4,051.69 6,469.91
XSWX:SAN
91GF Score
Sanofi SA XSWX:SAN
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of CHF6,470 Mil mean?
Sanofi (XSWX:SAN) has a Short-Term Debt of CHF6,470 Mil as of Jun. 2026.
Is Sanofi's Short-Term Debt too high?
Sanofi's current Short-Term Debt is CHF6,470 Mil. Overall, Sanofi has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Short-Term Debt compare to LLY and JNJ?
Sanofi's Short-Term Debt of CHF6,470 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Sanofi's current Short-Term Debt is CHF6,470 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current Short-Term Debt of CHF6,470 Mil. The stock's GF Value™ is CHF103.32, compared to a current price of CHF73.20 — trading 29.2% below its estimated fair value. The current Short-Term Debt is CHF6,470 Mil. Sanofi's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current Short-Term Debt is CHF6,470 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (XSWX:SAN) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of CHF73.20 is trading 29.2% below its estimated GF Value™ of CHF103.32.

Key valuation signals for XSWX:SAN:

  • Short-Term Debt: CHF6,470 Mil
  • GF Value™: CHF103.32 vs. price of CHF73.20 (29.2% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
91GF Score

Get the complete analysis for XSWX:SAN

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF73.20
Price
CHF103.32
GF Value